BR112022011337A2 - Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo - Google Patents

Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo

Info

Publication number
BR112022011337A2
BR112022011337A2 BR112022011337A BR112022011337A BR112022011337A2 BR 112022011337 A2 BR112022011337 A2 BR 112022011337A2 BR 112022011337 A BR112022011337 A BR 112022011337A BR 112022011337 A BR112022011337 A BR 112022011337A BR 112022011337 A2 BR112022011337 A2 BR 112022011337A2
Authority
BR
Brazil
Prior art keywords
progression
injury
disease
treat
delay
Prior art date
Application number
BR112022011337A
Other languages
English (en)
Inventor
Paul Robert
F Ward Michael
Long Hua
Lu Shiao-Ping
Rizwan Siddiqui Omer
Rosenthal Arnon
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of BR112022011337A2 publication Critical patent/BR112022011337A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

MÉTODO PARA TRATAR E/OU RETARDAR A PROGRESSÃO DE UMA DOENÇA OU LESÃO EM UM INDIVÍDUO. A presente divulgação é geralmente direcionada a anticorpos, por exemplo, anticorpos monoclonais, quiméricos, humanizados, fragmentos de anticorpos, etc., que se ligam especificamente a um ou mais epítopos dentro de uma proteína CD33, por exemplo, CD33 humano ou um CD33 de mamífero, e têm características funcionais melhoradas e/ou aprimoradas. A presente divulgação é ainda direcionada aos métodos de tratamento e/ou retardamento da progressão de uma doença ou lesão em um indivíduo pela administração de tais anticorpos.
BR112022011337A 2019-12-12 2020-12-11 Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo BR112022011337A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947455P 2019-12-12 2019-12-12
PCT/US2020/064461 WO2021119400A1 (en) 2019-12-12 2020-12-11 Methods of use of anti-cd33 antibodies

Publications (1)

Publication Number Publication Date
BR112022011337A2 true BR112022011337A2 (pt) 2022-08-23

Family

ID=74141926

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011337A BR112022011337A2 (pt) 2019-12-12 2020-12-11 Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo

Country Status (11)

Country Link
US (1) US20230035072A1 (pt)
EP (1) EP4073119A1 (pt)
JP (1) JP2023506014A (pt)
KR (1) KR20220127243A (pt)
CN (1) CN115066437A (pt)
AU (1) AU2020403021A1 (pt)
BR (1) BR112022011337A2 (pt)
CA (1) CA3161206A1 (pt)
IL (1) IL293772A (pt)
MX (1) MX2022007156A (pt)
WO (1) WO2021119400A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0308936B1 (en) 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JP2002514895A (ja) 1995-09-28 2002-05-21 アレクション、ファーマスーティカルズ、インコーポレーテッド ブタ細胞相互作用タンパク質
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2006504971A (ja) 2002-11-01 2006-02-09 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト マトリックス支援レーザー脱離イオン化−飛行時間型質量分析によるタンパク質アイソフォームの定量的解析
AP2007004034A0 (en) 2004-12-31 2007-06-30 Genentech Inc Polypeptides sthat bind br3 and uses thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
EP2001490A1 (en) 2006-03-15 2008-12-17 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
AU2008298603B2 (en) 2007-09-14 2015-04-30 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
US11174313B2 (en) * 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
AU2016276981B2 (en) * 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
CR20190486A (es) * 2017-08-03 2020-02-10 Alector Llc Anti-cd33 antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN115066437A (zh) 2022-09-16
US20230035072A1 (en) 2023-02-02
KR20220127243A (ko) 2022-09-19
WO2021119400A1 (en) 2021-06-17
CA3161206A1 (en) 2021-06-17
JP2023506014A (ja) 2023-02-14
MX2022007156A (es) 2022-09-07
EP4073119A1 (en) 2022-10-19
AU2020403021A1 (en) 2022-06-23
IL293772A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
PH12019502459A1 (en) Anti-trem2 antibodies and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
WO2016201389A3 (en) Anti-cd33 antibodies and methods of use thereof
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
MX2020012639A (es) Anticuerpos frente a entpd2, terapias de combinacion y metodos de uso de los anticuerpos y las terapias de combinacion.
BR112022019892A2 (pt) Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
BR112022011337A2 (pt) Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
BR112022009265A2 (pt) Método de tratamento do câncer e método para aumentar, potencializar ou estimular uma resposta ou função imune
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
BR112023025188A2 (pt) Métodos de uso de anticorpos anti-sortilina
BR112022008184A2 (pt) Métodos de tratamento do câncer e para aumentar, potencializar ou estimular uma resposta ou função imune
BR112022009147A2 (pt) Métodos de tratamento do câncer e métodos para aumentar, potencializar ou estimular uma resposta ou função imune
EA201992319A1 (ru) Анти-cd33 антитела и способы их применения
AR112401A1 (es) Anticuerpos anti-cd33 y métodos para utilizarlos
EA202092279A1 (ru) Антитела к mica и/или micb и их применение

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]